Table 2.

Clinical endpoints.

N = 75
CRS
 Median time to CRS2 days
 Median time to max CRS4 days
 CRS all grades, no. (%)72 (96)
 Grade ≥3 CRS, no. (%)12 (16)
 Grade 5 CRS, no. (%)3 (4)
 Use of tocilizumab, no. (%)43 (57)
 Use of steroids, no. (%)41 (55)
Neurotoxicity
 Median time to NT5 days
 Median time to max NT6 days
 NT all grades, no. (%)50 (67)
 Grade ≥3 NT, no. (%)23 (31)
D90 response (N = 68)
 CR + PR, no. (%)36 (53)
 Complete response, no. (%)29 (43)
 NRM, no. (%)4 (6)
 Disease related mortality, no. (%)9 (13)
  • Note: CRS and NT were graded prospectively. CRS was defined and graded using the ASTCT grading guidelines (4). Neurologic toxicity was graded using the CAR T-cell-therapy-associated (CARTOX) working group guidelines (6). Tumor response was determined by the treating physician per Lugano 2014 classification (20).

  • Abbreviation: NRM, nonrelapse mortality.